Ex Vivo and In Vivo Characterization of Interpolymeric BlendNanoenabled Gastroretentive Levodopa Delivery Systems

Abstract EN

One approach for delivery of narrow absorption window drugs is to formulate gastroretentive drug delivery systems.

This study was undertaken to provide insight into in vivo performances of two gastroretentive systems (PXLNET and IPB matrices) in comparison to Madopar® HBS capsules.

The pig model was used to assess gastric residence time and pharmacokinetic parameters using blood, cerebrospinal fluid (CSF), and urine samples.

Histopathology and cytotoxicity testing were also undertaken.

The pharmacokinetic parameters indicated that levodopa was liberated from the drug delivery systems, absorbed, widely distributed, metabolized, and excreted.

Cmax were 372.37, 257.02, and 461.28 ng/mL and MRT were 15.36, 14.98, and 13.30 for Madopar HBS capsules, PXLNET, and IPB, respectively.

In addition, X-ray imaging indicated that the gastroretentive systems have the potential to reside in the stomach for 7 hours.

There was strong in vitro-in vivo correlation for all formulations with r2 values of 0.906, 0.935, and 0.945 for Madopar HBS capsules, PXLNET, and IPB, respectively.

Consequently, PXLNET and IPB matrices have pertinent potential as gastroretentive systems for narrow absorption window drugs (e.g., L-dopa) and, in this application specifically, enhanced the central nervous system and/or systemic bioavailability of such drugs.